Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Blood (2018) 132 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2018-99-114168

Published: 2018

Journal Articles

Low Circulating B Lymphocytes in Newly Diagnosed Follicular and Diffuse Large B Cell Lymphoma: Differences Compared to Normal Subjects and Possible Prognostic Role

Riccardo Bruna, Massimo Geuna, Delia Rota Scalabrini, MD, Alessandro Cignetti, MD PhD, Nathalie Santoro, Daniela Gottardi, MD, Roberto Passera, Corrado Tarella, MD Prof

Blood (2017) 130 (Supplement 1): 1482.

https://doi.org/10.1182/blood.V130.Suppl_1.1482.1482

Published: 2017

Journal Articles

Sequential High-Dose Chemotherapy Reinduction Followed By Haploidentical Transplantation in Acute Leukemias

Lucia Brunello, Roberto Passera, Chiara Maria Dellacasa, Luisa Giaccone, Ernesta Audisio, Dario Ferrero, Stefano D'Ardia, Bernardino Allione, Semra Aydin, Moreno Festuccia, Elena Crisà, Enrico Maffini, Sara Butera, Mario Boccadoro, Umberto Vitolo, MD, Alessandro Busca, Benedetto Bruno

Blood (2017) 130 (Supplement 1): 4588.

https://doi.org/10.1182/blood.V130.Suppl_1.4588.4588

Published: 2017

Journal Articles

Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study

Blood (2017) 130 (Supplement 1): 3128.

https://doi.org/10.1182/blood.V130.Suppl_1.3128.3128

Published: 2017

Journal Articles

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Blood (2016) 128 (22): 1145.

https://doi.org/10.1182/blood.V128.22.1145.1145

Published: 2016

Journal Articles

Hematopoietic Cell Transplantation Comorbidity Index As Prognostic Variable in Patients with Invasive Fungal Infections

Alessandro Busca, MD, Roberto Passera, PharmD, PhD, Enrico Maffini, MD, Lucia Brunello, MD, Chiara Maria Dellacasa, MD, Semra Aydin, MD PhD, Chiara Frairia, MD, Sara Manetta, MD, Sara Butera, MD, Giorgia Iovino, MD, Luisa Giaccone, MD PhD, Mario Boccadoro, MD, Umberto Vitolo, Benedetto Bruno, MD PhD

Blood (2015) 126 (23): 5526.

https://doi.org/10.1182/blood.V126.23.5526.5526

Published: 2015

Journal Articles

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Corrado Tarella, MD, Angela Gueli, Federica Delaini, Anna Maria Barbui, MD, Riccardo Bruna, Daniele Caracciolo, Daniela Gottardi, Giuseppe Gritti, MD, Roberto Passera, PharmD, PhD, Safaa Ramadan, PhD MD, Andrea Rossi, MD, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3989.

https://doi.org/10.1182/blood.V126.23.3989.3989

Published: 2015

Journal Articles

Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Benedetto Bruno, MD PhD, Simone Ferrero, MD, Daniela Drandi, Moreno Festuccia, MD, Francesca Patriarca, MD, Nicola Mordini, MD, Silvia Cena, PhD, Daniela Barbero, PhD, Luigia Monitillo, PhD, Federica Ferrando, MD, Lucia Brunello, MD, Renato Fanin, MD, Paola Ghione, MD, Paola Omedè, PhD, Luisa Giaccone, MD PhD, Antonio Palumbo, MD, Roberto Passera, PhD, Mario Boccadoro, MD, Marco Ladetto, MD

Blood (2014) 124 (21): 44.

https://doi.org/10.1182/blood.V124.21.44.44

Published: 2014

Journal Articles

Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study

Antonio Palumbo, MD, Davide Rossi, MD PhD, Sara Bringhen, MD, Alessandra Larocca, MD, Fabiana Gentilini, MDPhD, Lorenzo De Paoli, Paola Omedè, PhD, Stelvio Ballanti, MD, Federica Cavallo, MD, Roberto Passera, Anna Marina Liberati, MD, Mario Boccadoro, MD, Gianluca Gaidano, Pieter Sonneveld, MDPhD, Paolo Corradini, MD

Blood (2014) 124 (21): 175.

https://doi.org/10.1182/blood.V124.21.175.175

Published: 2014

Journal Articles

Immunophenotypic Response After Allografting In Multiple Myeloma

Luisa Giaccone, MD, Lucia Brunello, Roberto Passera, Moreno Festuccia, MD, Milena Gilestro, Enrico Maffini, Federica Ferrando, Mario Boccadoro, MD, Paola Omedè, MD, Benedetto Bruno

Blood (2013) 122 (21): 3371.

https://doi.org/10.1182/blood.V122.21.3371.3371

Published: 2013

Journal Articles

Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM

Blood (2013) 122 (21): 4290.

https://doi.org/10.1182/blood.V122.21.4290.4290

Published: 2013

Journal Articles

Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

Blood (2013) 122 (21): 2077.

https://doi.org/10.1182/blood.V122.21.2077.2077

Published: 2013

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

Blood (2013) 122 (8): 1376–1383.

https://doi.org/10.1182/blood-2013-02-483073

Published: 2013

Includes: Supplemental data

Journal Articles

Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy

Corrado Tarella, MD, Angela Gueli, MD, Federica Delaini, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, Huijing Hu, MD, Daniela Gottardi, MD, Roberto Passera, PharmD PhD, Alessandro Rambaldi, MD

Blood (2012) 120 (21): 305.

https://doi.org/10.1182/blood.V120.21.305.305

Published: 2012

Journal Articles

High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma

Marco Ladetto, MD, Simone Ferrero, MD, Daniela Drandi, PhD, Paola Omedè, PhD, Francesca Patriarca, MD, Nicola Mordini, MD, Silvia Cena, PhD, Daniela Barbero, PhD, Luigia Monitillo, PhD, Luisa Giaccone, MD, Alberto Rocci, MD, Sara Barbiero, MD, Moreno Festuccia, MD, Andrea Gallamini, MD, Renato Fanin, MD, Roberto Passera, PhD, Antonio Palumbo, MD, Mario Boccadoro, MD, Benedetto Bruno, MD

Blood (2012) 120 (21): 4204.

https://doi.org/10.1182/blood.V120.21.4204.4204

Published: 2012

Journal Articles

Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM)

Marco Ladetto, MD, Monika Bruggemann, Simone Ferrero, MD, Francois Pepin, Daniela Drandi, PhD, Luigia Monitillo, PhD, Antonio Palumbo, MD, Roberto Passera, PhD, Mario Boccadoro, MD, Victoria Carlton, PhD, Heiko Trautmann, Malek Faham, MD, PhD, Christiane Pott

Blood (2012) 120 (21): 788.

https://doi.org/10.1182/blood.V120.21.788.788

Published: 2012

Journal Articles

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Alessandro Rambaldi, MD, Cristina Boschini, Federica Delaini, BiolSC, Elena Oldani, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Angela Gueli, MD, Alberto De Crescenzo, MD, Roberto Passera, PhD, Liliana Devizzi, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD

Blood (2012) 120 (21): 1553.

https://doi.org/10.1182/blood.V120.21.1553.1553

Published: 2012

Journal Articles

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Patrizia Pregno, Annalisa Chiappella, Marilena Bellò, Barbara Botto, Simone Ferrero, Silvia Franceschetti, Francesca Giunta, Marco Ladetto, Giorgio Limerutti, Massimo Menga, Maura Nicolosi, Giorgio Priolo, Benedetta Puccini, Luigi Rigacci, Flavia Salvi, Luca Vaggelli, Roberto Passera, Gianni Bisi, Umberto Vitolo

Blood (2012) 119 (9): 2066–2073.

https://doi.org/10.1182/blood-2011-06-359943

Published: 2012

Journal Articles

Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry

Blood (2011) 118 (21): 2009.

https://doi.org/10.1182/blood.V118.21.2009.2009

Published: 2011

NARROW

The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Low Circulating B Lymphocytes in Newly Diagnosed Follicular and Diffuse Large B Cell Lymphoma: Differences Compared to Normal Subjects and Possible Prognostic Role

Sequential High-Dose Chemotherapy Reinduction Followed By Haploidentical Transplantation in Acute Leukemias

Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Hematopoietic Cell Transplantation Comorbidity Index As Prognostic Variable in Patients with Invasive Fungal Infections

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study

Immunophenotypic Response After Allografting In Multiple Myeloma

Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM

Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy

High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma

Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM)

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only